DoMore Diagnostics and Partners Announce Clinical Collaboration to Validate Histotype Px® Colorectal in Mexican Patients
OSLO – July 3, 2025 – DoMore Diagnostics, a leader in AI precision medicine for cancer, is launching an important collaboration with Mexican hospitals to validate the Histotype Px® Colorectal digital biomarker. The collaboration is a joint initiative with Hospital Civil of Guadalajara, the Jalisco Medical Cluster, and Hospital San Javier led by Drs. Eduardo Navarro and Fernando Zazueta. This collaboration derives from the efforts of the Embassy of Mexico in Norway to bring together key actors in the innovation sector in both countries.
The retrospective study will involve up to 300 Mexican patients who have undergone surgery for stage II or III colorectal cancer. Digitized pathology slides and clinical data will be analyzed using Histotype Px Colorectal to assess its ability to predict outcomes and treatment benefit.
Colorectal cancer is the third most common cancer in Mexico, and most stage II and stage III patients are currently treated with chemotherapy after surgery. However, most patients do not benefit from chemotherapy and only suffer from side effects, adding strain to the already overburdened health system.
“There is a high medical need to personalize cancer treatment in Mexico. We can increase the quality of care and reduce waiting times by selecting the patients who are likely to benefit from chemotherapy,” said Dr. Eduardo Navarro, colorectal surgeon, at Hospital Civil of Guadalajara and member of the Jalisco Medical Cluster. “Validating Histotype Px Colorectal offers an opportunity to identify patients who can safely avoid chemotherapy, thereby improving care and freeing up resources.”
"As a pathologist, I value how seamlessly Histotype Px Colorectal integrates into our existing laboratory workflow," said Dr. Fernando Zazueta at Hospital San Javier. "It uses routine digitized H&E slides, and delivers fast, reliable results. For oncologists, it is a powerful tool to guide personalized treatment decisions. And for patients, it could mean better outcomes and more confidence around difficult treatment decisions."
“We are honored to work with our clinical partners in Mexico on this important project,” said Torbjørn Furuseth, CEO and Co-founder of DoMore Diagnostics. “By validating Histotype Px Colorectal in a Mexican population, we’re expanding the clinical documentation and scientific foundation of our AI-driven digital biomarker, and we’re also addressing an urgent medical need in Mexico. This is a compelling example of how AI can deliver immediate impact in cancer care worldwide.”
About Hospital Civil of Guadalajara
Established in 1794 by Bishop Fray Antonio Alcalde, Hospital Civil of Guadalajara is one of Mexico’s oldest and most respected public tertiary‑care institutions. Today, as an autonomous entity of the Jalisco state government and affiliated with the University of Guadalajara, it operates three major facilities including the historic Fray Antonio Alcalde hospital, the Dr. Juan I. Menchaca hospital, and the newly inaugurated Oriente campus. It serves nearly 29% of Jalisco’s population. With over 1.15 million patient visits, 5.5 million lab samples, 230,000 imaging studies, and 3,000 pathology analyses annually, the hospital is equipped with cutting‑edge technology. This robust infrastructure positions Hospital Civil as a national leader in medical education, research, and high‑complexity care.
About the Jalisco Medical Cluster
The Jalisco Medical Cluster is a leading health‑tech ecosystem in western Mexico, uniting academia, industry, government, and civil society under a “quadruple helix” model to accelerate innovation in healthcare. Over the past five years the cluster has grown into one of the nation’s top hubs for medical device development, thanks to close collaboration with universities, state innovation agencies, and international partners from Germany, Norway, the UK and beyond. The cluster supports more than 800 healthcare companies in Jalisco, over 350 dedicated to medical devices, leveraging robust R&D infrastructure, skilled biomedical engineers, and regulatory linkages to COFEPRIS. With a vision to transform public health through homegrown solutions, the Jalisco Medical Cluster offers an ideal platform for introducing Histotype Px Colorectal and accelerating access to personalized cancer care across Mexico.
About Hospital San Javier
Founded on December 12, 1994, Hospital San Javier is a premier private, tertiary-care facility in Guadalajara, recognized for its pioneering use of cutting-edge medical technology in Western Mexico. It was the first hospital in Latin America, to introduce Gamma Knife radiosurgery, and remains the only private oncology center in western Mexico offering comprehensive cancer care including advanced radiotherapy, chemotherapy, pathology services, and multidisciplinary support all under one roof. With international- and national-accreditations, a 154‑bed capacity, an experienced international team of 3,000+ specialists, and on-site amenities ranging from a helipad to blood bank and neonatal ICU, Hospital San Javier delivers high-specialty, patient-centered care to both local and international patients.
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Our unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
Histotype Px is a registered trademark in the European Union. Trademark registration status may vary by country.
For more information, please visit:
www.domorediagnostics.com
LinkedIn
The Lancet publication
The Lancet Oncology publication
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com